Profile
ACHL VRTX REGN SGEN ARGX ALNY
Company Name Achilles Therapeutics plc Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $60.83M $128.84B $64.28B $43.15B $39.39B $33.74B
Employees 0.20K 6.10K 15.16K 3.26K 1.60K 2.23K
CEO Dr. Iraj Ali Ph.D. Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc. Dr. Yvonne L. Greenstreet M.B.A., M.D.
Ratings
ACHL VRTX REGN SGEN ARGX ALNY
Quant Rating Score 3 2 4 3 3 1
Quant Rating Neutral Sell Buy Neutral Neutral Strong Sell
Trading
ACHL VRTX REGN SGEN ARGX ALNY
Last Close $1.48 $429.6 $547.67 $228.74 $569.12 $258.35
High 52 $1.49 $516.74 $1201.76 $228.74 $671.75 $296.75
Low 52 $0.7 $396.64 $546.39 $228.74 $356.01 $146.93
Price vs. 52 Week High -0.67 % -16.86 % -54.43 % 0 % -15.28 % -12.94 %
Price vs. 52 Week Low 111.43 % 8.31 % 0.23 % 0 % 59.86 % 75.83 %
Total Return
ACHL VRTX REGN SGEN ARGX ALNY
1 Month Return 0 % -10.93 % -4.95 % 0 % 0.94 % 6.21 %
3 Month Return 7.25 % -8.46 % -22.81 % 0 % -11.99 % -6.46 %
6 Month Return 40.95 % -16.86 % -33.89 % 0 % -4.51 % -6.88 %
9 Month Return 91.81 % -8.29 % -51.59 % 0 % 6.38 % -4.14 %
YTD Return 29.82 % 6.68 % -23.12 % 0 % -7.46 % 9.79 %
1 Year Return 61.11 % 2.53 % -43.42 % 0 % 48.77 % 70.67 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACHL VRTX REGN SGEN ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.15 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -42.87 % -1.65 % 3.85 % -2.27 % -44.32 % -1.49 %
Dividend Per Share (TTM) - - 0.88 % - - -
Payout Ratio (TTM) - - 2.08 % - - -
Growth
ACHL VRTX REGN SGEN ARGX ALNY
Asset Growth -26.73 % -0.87 % -1.21 %
Gross Profit Growth -28.3 % 10.25 % 22.93 %
Revenue Growth - 11.66 % 24.65 %
Revenue 3 Year - 45.6 % 91.56 %
Revenue 5 Year - 163.93 % 215.48 %
Revenue 10 Year - 1632.15 % 494.04 %
EBIT Growth 3.99 % -93.69 % 10.13 %
Net Income Growth 2.12 % -114.8 % 9.51 %
Net Income 3 Yeari Growth Per Share -113.25 % -122.89 % -763.59 %
Net Income 5 Yeari Growth Per Share 86.28 % -145.38 % -276.93 %
Net Income 10 Yeari Growth Per Share 86.28 % 33.84 % -624.16 %
Operating Income Growth 3.99 % -105.41 % 10.13 %
Operating Cash Flow Growth (CFG) 18.62 % -113.93 % 9.07 %
Operating 3 Year CFG -94.98 % -118.65 % -147.99 %
Operating 5 Year CFG -8546.04 % -131.3 % -195.86 %
Operating 10 Year CFG -8546.04 % 12.43 % -2622.09 %
EPS Growth 4.4 % -114.8 % 10.81 %
EPS Diluted Growth 4.4 % -114.97 % 10.81 %
Book Value Per Share -29.25 % -6.59 % -9.83 %
Share Holder 3 Year Equity Growth Per Share -23.6 % 62.6 % 33.72 %
Share Holder 5 Year Equity Growth Per Share -84.77 % 168.85 % 220.81 %
Share Holder 10 Year Equity Growth Per Share -84.77 % 1265.7 % 691.19 %
Dividend Per Share Growth - - -
Dividend 3 Year Growth Per Share - - -
Dividend 5 Year Growth Per Share - - -
Dividend 10 Year Growth Per Share - - -
Debt Growth -46.19 % 116.42 % -23.28 %
Free Cash Flow Growth 26.1 % -124.1 % 3.67 %
Updated On 31 Dec 2023 31 Dec 2024 31 Dec 2022
Profitability
ACHL VRTX REGN SGEN ARGX ALNY
Gross Profit Margin TTM - 86.09 % 84.94 % 72.37 % 46.33 % 86.01 %
Return on Assets TTM -54.64 % -2.38 % 11.98 % -11.76 % 13.45 % -6.4 %
Return on Equity TTM -54.57 % -3.28 % 14.77 % -16.53 % 16.83 % -509.33 %
Return on Capital Employed TTM -69.28 % -1.3 % 11.35 % -16.87 % -0.31 % -3.68 %
Net Income Per EBT TTM 100.74 % -215.53 % 90.27 % 100.55 % 25990.14 % 75.89 %
EBT Per Ebit TTM 92.18 % -100.69 % 129.3 % 94.01 % -18.79 % 308.03 %
EBIT Per Revenue TTM - -2.24 % 27.37 % -36.09 % -0.77 % -4.91 %
Cash Flow To Debt Ratio TTM -876.73 % -28.16 % 146.15 % -185.98 % -201.37 % -3.47 %
Receivables Turnover TTM - 6.84 2.53 1.98 2.46 5.62
Payables Turnover TTM 0.83 3.71 3.01 1.54 1.83 3.37
Inventory Turnover TTM - 1.27 0.66 0.65 2.93 5.01
Fixed Asset Turnover TTM - 425.82 % 300.07 % 256.83 % 5106.8 % 337.41 %
Asset Turnover TTM - 48.84 % 37.52 % 34.46 % 35.83 % 55.72 %
Operating Cash Flow Per Share TTM -0.79 -1.91 37.05 -1.12 -1.07 -0.35
Free Cash Flow Per Share TTM -0.8 -3.07 28.3 -1.62 -1.09 -0.58
Cash Per Share TTM 212.86 % 2375.11 % 7825.12 % 657.5 % 4597.04 % 2024.29 %
Operating Cash Flow Sales Ratio TTM - -4.48 % 28.06 % -16.85 % -3.54 % -1.92 %
Free Cash Flow Operating Cash Flow Ratio TTM 102.33 % 160.43 % 76.4 % 144.14 % 102.26 % 167.11 %
Cash Flow Coverage Ratios TTM -876.73 % -28.16 % 146.15 % -185.98 % -201.37 % -3.47 %
Price To Free Cash Flows Ratio TTM -1.87 -163.02 21.29 -141.85 -505.86 -447.57
Price To Operating Cash Flows Ratio TTM -1.89 -261.97 16.35 -203.89 -601.06 -745.64
Price Cash Flow Ratio TTM -1.89 -261.97 16.35 -203.89 -601.06 -745.64
Income Statement (TTM)
ACHL VRTX REGN SGEN ARGX ALNY
Revenue $0B $11.02B $14.2B $1.96B $2.19B $2.25B
Gross Profit $-0B $9.49B $12.23B $1.55B $1.96B $1.92B
Gross Profit Ratio 0% 86.11% 86.13% 79.1% 89.62% 85.62%
EBITDA $-0.07B $0.48B $5.32B $-0.62B $0B $-0.18B
Net Income $-0.07B $-0.54B $4.41B $-0.61B $0.83B $-0.28B
EPS Diluted -1.74 -2.08 38.34 -3.3 12.78 -2.16
Balance Sheet (MRQ)
ACHL VRTX REGN SGEN ARGX ALNY
Long Term Debt $0B $1.66B $1.98B $0.04B $0.03B $0B
Total Liabilities $0.02B $6.12B $8.41B $0.87B $0.7B $4.17B
Total Equity $0.14B $16.41B $29.35B $2.8B $5.5B $0.07B
Total Investments $0B $6.65B $15.42B $1.42B $1.93B $1.73B
Total Debt $0B $1.75B $2.7B $0.04B $0.04B $1.3B
Total Assets $0.16B $22.53B $37.76B $3.67B $6.2B $4.3B
Cash Flow Statement (TTM)
ACHL VRTX REGN SGEN ARGX ALNY
Net Income $-0.07B $-0.54B $4.41B $-0.61B $0.8B $-0.28B
Inventory $0B $-0.52B $-0.62B $-0.23B $-0.09B $0.01B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.05B $-0.49B $4.42B $-0.45B $-0.08B $-0.01B
Capital Expenditure $-0B $-0.3B $-0.76B $-0.08B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.375
ABCL AbCellera Biologics Inc. 2.04
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.405
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.0035
ABPWW 0.02
ABSI Absci Corporation 2.75
ABUS Arbutus Biopharma Corporation 3.295
ABVC ABVC BioPharma, Inc. 1.28
ABVX Abivax SA American Depositary Shares 6.76
ACAD ACADIA Pharmaceuticals Inc. 17.33
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.5957
ACGN Aceragen, Inc. 0.3849
ACHV Achieve Life Sciences, Inc. 2.42
ACIU AC Immune SA 1.68
ACLX Arcellx, Inc. 56.01
ACRV Acrivon Therapeutics, Inc. Common Stock 1.185
ETFs With Exposure to ACHL
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0.01 118.145
BIB ProShares Ultra Nasdaq Biotechnology 0 40.855
IBBQ Invesco Nasdaq Biotechnology ETF 0 19.76
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 5.75
Unlock